Updating results

2729 results

Sort: Relevance | Date

TopClosure Tension Relief System for wound closure (MIB97)

Advice on the use of the TopClosure Tension Relief System for wound closure to aid local decision-making

Medtech innovation briefing Published March 2017

U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)

Advice on the use of the U-Drain drainage system for people needing night drainage of urine or dialysis fluid to aid local decision-making

Medtech innovation briefing Published February 2017

Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

Advice on the use of the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis to aid local decision-making

Medtech innovation briefing Published January 2017

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017

Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

Summary of the evidence on conjugated oestrogens and bazedoxifene acetate for oestrogen deficiency symptoms to inform local NHS planning and decision-making

Evidence summary Published December 2016

Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS

Evidence summary Published June 2019

Pulmonary sarcoidosis: infliximab (ES2)

Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published December 2016

Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)

Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS

Evidence summary Published February 2019

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS

Evidence summary Published June 2018

Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

ES12 Key points The content of this evidence summary

Evidence summary Published April 2017

Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

Evidence summary Published March 2017

Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

Evidence summary Published November 2016

Hyperhidrosis: oxybutynin (ES10)

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...

Evidence summary Published June 2014

Premature ejaculation: dapoxetine (ESNM40)

Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

Evidence summary Published May 2014

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

Induction of labour: misoprostol vaginal delivery system (ESNM38)

Summary of the evidence on the misoprostol vaginal delivery system for induction of labour to inform local NHS planning and decision-making

Evidence summary Published March 2014 Last updated November 2014

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014

Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

Summary of the evidence on the fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler for asthma to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..

Evidence summary Published February 2014 Last updated March 2014

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

Summary of the evidence on fluticasone/formoterol (Flutiform) combination inhaler for treating asthma to inform local NHS planning and decision-making

Evidence summary Published October 2012

Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)

Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making

Evidence summary Published December 2013

Type 2 diabetes: lixisenatide (ESNM26)

Summary of the evidence on lixisenatide (glucagon-like peptide-1 [GLP-1] mimetic) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Type 2 diabetes: insulin degludec (ESNM25)

Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Type 1 diabetes: insulin degludec (ESNM24)

Summary of the evidence on insulin degludec for treating type 1 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published June 2013

Autoimmune haemolytic anaemia: rituximab (ESUOM39)

Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Antipsychotics in people living with dementia (KTT7)

This document summarises the evidence base on antipsychotics in people living with dementia. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Hypnotics (KTT6)

This document summarises the evidence base on hypnotics. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Asthma: medicines safety priorities (KTT5)

This document summarises the evidence base on asthma: medicines safety priorities. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Lipid-modifying drugs (KTT3)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Chemotherapy dose standardisation (KTT22)

This document summarises the evidence base on chemotherapy dose standardisation. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published February 2018 Last updated September 2019

Medicines optimisation in chronic pain (KTT21)

This document summarises the evidence base on medicines optimisation in chronic pain. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2017 Last updated September 2019

Safer insulin prescribing (KTT20)

This document summarises the evidence base on safer insulin prescribing. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2017 Last updated September 2019

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2017 Last updated September 2019

Multimorbidity and polypharmacy (KTT18)

This document summarises the evidence base on multimorbidity and polypharmacy. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2017 Last updated September 2019

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published February 2016 Last updated September 2019

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants, including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published February 2016 Last updated September 2019

Biosimilar medicines (KTT15)

The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance.

Key therapeutic topic Published February 2016 Last updated February 2018

Smart One for measuring lung function (MIB96)

Advice on the use of Smart One for measuring lung function to aid local decision-making

Medtech innovation briefing Published February 2017

eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)

Advice on the use of eazyplex SuperBug kits for detecting carbapenemase-producing organisms (bacteria) to aid local decision-making

Medtech innovation briefing Published February 2017

Smartinhaler for asthma (MIB90)

Advice on the use of Smartinhaler for monitoring the activation of asthma inhalers to aid local decision-making

Medtech innovation briefing Published January 2017

Needle-free arterial non-injectable connector (MIB85)

Advice on the use of needle-free arterial non-injectable connector through which blood samples can be collected to aid local decision-making

Medtech innovation briefing Published October 2016